Cargando…

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice

Background: This retrospective study was conducted to evaluate the safety and efficacy of ambrisentan combination therapy with phosphodiesterase type 5 (PDE5) inhibitors in Japanese patients with pulmonary arterial hypertension (PAH). Methods and Results: PAH patients who received ambrisentan for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kataoka, Masaharu, Satoh, Toru, Matsubara, Hiromi, Yamamoto, Koji, Inada, Tsukasa, Umezawa, Kazunari, Takahashi, Tomohiko, Nakano, Atsushi, Fukuda, Keiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889478/ https://www.ncbi.nlm.nih.gov/pubmed/33693149 http://dx.doi.org/10.1253/circrep.CR-19-0029

Ejemplares similares

Arterial methemoglobin level predicts therapeutic effectiveness of the PDE5 inhibitors in patients with in idiopathic pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2011)

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
por: Kimura, Mai, et al.
Publicado: (2015)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
por: Mietens, Andrea, et al.
Publicado: (2011)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease
por: Cesarini, Valeriana, et al.
Publicado: (2020)

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
por: Rybalkina, Irina G, et al.
Publicado: (2011)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain
por: Liu, Jianrong, et al.
Publicado: (2016)

Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression
por: Catalano, Stefania, et al.
Publicado: (2019)

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging
por: Bailey, Justin J., et al.
Publicado: (2021)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection
por: Foulke-Abel, Jennifer, et al.
Publicado: (2020)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
por: Shafiee, Arman, et al.
Publicado: (2023)

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation
por: Dolce, Bernardo, et al.
Publicado: (2020)

A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population
por: Kimura, Mai, et al.
Publicado: (2017)

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
por: Chang, Jo-Fan, et al.
Publicado: (2019)

Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis
por: Dong, Liang, et al.
Publicado: (2019)

Rapid Screening and Quantitative Determination of Illegal Phosphodiesterase Type 5 Inhibitors (PDE-5i) in Herbal Dietary Supplements
por: Nguyen, Thi Oanh, et al.
Publicado: (2021)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension
por: Ueda, Yu, et al.
Publicado: (2019)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis
por: Egbert, Jeremy R., et al.
Publicado: (2016)

Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009)

Ambrisentan-induced severe asymptomatic thrombocytopenia
por: Kigitovica, Dana, et al.
Publicado: (2020)

Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
por: Karedath, Jithin, et al.
Publicado: (2023)

Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra
por: Rahardjo, Harrina E, et al.
Publicado: (2021)

Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis
por: Huyut, Zübeyir, et al.
Publicado: (2018)

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties
por: Amin, Kamelia M., et al.
Publicado: (2022)

Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertension　― Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers ―
por: Ishiguro, Midori, et al.
Publicado: (2020)

Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells
por: Dong, Hongli, et al.
Publicado: (2013)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
por: Inami, Takumi, et al.
Publicado: (2014)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia
por: Schroeder, Thies, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v529hfqfq3h82jsbpdq30kpe7r